Novel Program Supports Student Education and Future Careers in Patient Advocacy Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has made a founding, five-year gift to establish the University
It must be admitted that in the honor roll of modern problems, few sound as funny as “fatbergs.”“We were literally laughing, tears rolling down our faces, talking about all the things that had been discovered in this glob of waste,” said Laura Lady,.
The Company plans to work with the FDA to design a Phase 3 program in moderate-to-high systemic disease activity patients to begin in 2023, ahead of expectations - Horizon Therapeutics plc (Nasdaq:
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares. "This share repurchase program
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2022 list in the large company category. This is the sixth consecutive year